Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease.

NCT06418919 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT06418919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06418919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease.
Lead sponsor
The University of Hong Kong
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2020
Completion date
December 1, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

radiofrequency ablation treatment, relapsed graves' disease, thyroid; functional disturbance